CIBC Bancorp USA’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
CIBC Bancorp USA's CRSP Position: Q3 2026 in Review
CIBC Bancorp USA increased its CRISPR Therapeutics (CRSP) stake by 50% in Q3 2026, buying an estimated $188K and bringing the position to 10,408 shares worth $576K. The position accounts for ﹤0.01% of the portfolio, ranked #1290.
CIBC Bancorp USA first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. 504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- CIBC Bancorp USA held 10,408 shares of CRISPR Therapeutics worth $576K as of Q3 2026.
- CIBC Bancorp USA bought 3,486 CRISPR Therapeutics shares in Q3 2026, an estimated $188K.
- CRISPR Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1290 holding.
- CIBC Bancorp USA first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
- 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.